Subtopic Deep Dive
Relapse Risk and Salvage Therapy in ALL
Research Guide
What is Relapse Risk and Salvage Therapy in ALL?
Relapse Risk and Salvage Therapy in ALL identifies genetic markers like IKZF1 deletion and Ph-like lesions that predict poor outcomes post-remission and evaluates targeted salvage options such as kinase inhibitors for relapsed acute lymphoblastic leukemia patients.
Research shows IKZF1 deletion strongly associates with adverse prognosis in B-cell-progenitor ALL (Mullighan et al., 2009, 1420 citations). Ph-like ALL features kinase-activating lesions targetable by tyrosine kinase inhibitors (Roberts et al., 2014, 1347 citations). Comprehensive reviews detail relapse management strategies amid high frontline cure rates (Terwilliger and Abdul-Hay, 2017, 1228 citations).
Why It Matters
Relapse occurs in 15-20% of childhood ALL cases despite frontline cure rates exceeding 90%, making salvage therapy critical for the 30-50% salvageable patients (Hunger et al., 2012, 1168 citations). IKZF1 alterations identify high-risk groups needing intensified monitoring and novel regimens (Mullighan et al., 2009). Ph-like ALL kinase targets enable precision salvage with TKIs, improving post-relapse survival (Roberts et al., 2014). Advances reduce long-term toxicities while addressing extramedullary relapse sites.
Key Research Challenges
Predicting Relapse Risk Accurately
Distinguishing early marrow from extramedullary relapse patterns remains difficult despite cytogenetic refinements. IKZF1 deletion predicts poor outcomes but requires integration with minimal residual disease (MRD) data (Mullighan et al., 2009). High-risk subgroups like Ph-like ALL demand better upfront identification (Roberts et al., 2014).
Developing Effective Salvage Regimens
Frontline chemotherapy successes highlight need for non-overlapping salvage agents post-relapse. Ph-like lesions suggest TKI utility, but resistance mechanisms persist (Roberts et al., 2014). Balancing efficacy with toxicity in multiply relapsed patients challenges standard approaches (Terwilliger and Abdul-Hay, 2017).
Managing Treatment Toxicities
High-dose methotrexate in salvage risks acute kidney injury despite preventive measures (Howard et al., 2016, 836 citations). Cranial irradiation omission succeeds in frontline but complicates relapse CNS management (Pui et al., 2009). Long-term cardiac risks burden survivors requiring salvage (Mulrooney et al., 2009).
Essential Papers
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · 2010 · Blood · 1.9K citations
Abstract Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic abnorma...
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede, Christine Steudel, Brigitte Mohr et al. · 2002 · Blood · 1.7K citations
Constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplication (ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (TKD...
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
Charles G. Mullighan, Xiaoping Su, Jinghui Zhang et al. · 2009 · New England Journal of Medicine · 1.4K citations
Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL.
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner et al. · 2014 · New England Journal of Medicine · 1.3K citations
Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine k...
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T Terwilliger, Maher Abdul‐Hay · 2017 · Blood Cancer Journal · 1.2K citations
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Ching-Hon Pui, Dario Campana, Deqing Pei et al. · 2009 · New England Journal of Medicine · 1.2K citations
With effective risk-adjusted chemotherapy, prophylactic cranial irradiation can be safely omitted from the treatment of childhood ALL. (ClinicalTrials.gov number, NCT00137111.)
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
Stephen P. Hunger, Xiaomin Lu, Meenakshi Devidas et al. · 2012 · Journal of Clinical Oncology · 1.2K citations
Purpose To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Ch...
Reading Guide
Foundational Papers
Start with Mullighan et al. (2009) for IKZF1 prognostic role in B-ALL relapse (1420 citations), then Roberts et al. (2014) for Ph-like targetable lesions (1347 citations), and Pui et al. (2009) for frontline context informing salvage needs.
Recent Advances
Terwilliger and Abdul-Hay (2017, 1228 citations) updates comprehensive ALL management including relapse; Hunger et al. (2012, 1168 citations) reports survival trends highlighting persistent relapse challenge.
Core Methods
Cytogenetic risk stratification (Grimwade et al., 2010), genomic kinase lesion profiling (Roberts et al., 2014), MRD quantitation, and risk-adjusted chemotherapy without irradiation (Pui et al., 2009).
How PapersFlow Helps You Research Relapse Risk and Salvage Therapy in ALL
Discover & Search
Research Agent uses searchPapers and citationGraph on 'IKZF1 deletion ALL relapse' to map Mullighan et al. (2009) as central node with 1420 citations, then findSimilarPapers reveals Ph-like connections in Roberts et al. (2014). exaSearch uncovers 50+ related salvage therapy trials from OpenAlex's 250M+ papers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract relapse risk metrics from Mullighan et al. (2009), verifies survival curves via verifyResponse (CoVe), and runs PythonAnalysis with pandas to compute hazard ratios from IKZF1+ vs. IKZF1- cohorts. GRADE grading scores evidence as high for prognostic claims.
Synthesize & Write
Synthesis Agent detects gaps in Ph-like salvage data post-Roberts et al. (2014), flags contradictions between cytogenetic risks, and generates exportMermaid diagrams of relapse pathways. Writing Agent uses latexEditText, latexSyncCitations for Mullighan (2009), and latexCompile to produce a review manuscript on salvage strategies.
Use Cases
"Analyze survival data from IKZF1 deletion papers in relapsed ALL"
Research Agent → searchPapers('IKZF1 ALL relapse') → Analysis Agent → readPaperContent(Mullighan 2009) → runPythonAnalysis(pandas survival curves, matplotlib Kaplan-Meier plots) → researcher gets CSV of hazard ratios and GRADE-verified stats.
"Write LaTeX review on Ph-like ALL salvage therapies"
Synthesis Agent → gap detection(Roberts 2014) → Writing Agent → latexEditText(intro), latexSyncCitations(1347 cites), latexCompile → researcher gets compiled PDF with figure tables on TKI outcomes.
"Find code for ALL relapse prediction models"
Research Agent → paperExtractUrls(Mullighan 2009) → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for IKZF1 risk calculators with NumPy dependencies.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(ALL relapse 100+ papers) → citationGraph → DeepScan(7-step verify with CoVe checkpoints on Mullighan/Roberts data) → structured report on salvage gaps. Theorizer generates hypotheses linking IKZF1 to Ph-like resistance from 20 core papers. DeepScan analyzes MRD-relapse correlations with runPythonAnalysis stats.
Frequently Asked Questions
What defines relapse risk in ALL?
Relapse risk stratifies by genetics like IKZF1 deletion (poor prognosis, Mullighan et al., 2009) and Ph-like kinase lesions (TKI-targetable, Roberts et al., 2014).
What methods predict ALL relapse?
Cytogenetic classification (Grimwade et al., 2010), MRD assessment, and genomic profiling for IKZF1/Ph-like identify high-risk cases (Mullighan et al., 2009; Roberts et al., 2014).
What are key papers on ALL salvage?
Mullighan et al. (2009, 1420 citations) links IKZF1 to poor relapse outcomes; Roberts et al. (2014, 1347 citations) details Ph-like targets; Terwilliger and Abdul-Hay (2017, 1228 citations) reviews regimens.
What open problems exist in ALL relapse research?
Overcoming salvage resistance in IKZF1/Ph-like cases, distinguishing relapse sites, and minimizing toxicities like HDMTX nephropathy (Howard et al., 2016) remain unsolved.
Research Acute Lymphoblastic Leukemia research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Relapse Risk and Salvage Therapy in ALL with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers